Please assess the completion status of the following clinical trial:

Trial Title: Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Children under the age of 18 years.~2. IBD Diagnosis~3. Initiating Vedolizumab therapy~Exclusion Criteria:~1. Starting Vedolizumab to prevent post operative recurrence

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Vedolizumab (Type: EXPERIMENTAL): IV Vedolizumab 177mg/m2 Body Surface Area (BSA), max. 300mg Induction regimen: 0,2,6 and then every 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).